View allAll Photos Tagged DrugDevelopment
For the “Year of Clinical Trial Diversity”, FDA is launching a series of educational videos and materials to raise awareness about the importance of minorities participating in clinical trials. These videos stress the importance of why diversity is needed to help ensure medical products are safe and effective for everyone. Ms. Miller, who is living with sickle cell disease explains why clinical trials need diverse people to discover health disparities—conditions that appear differently in minorities, or affect minorities more frequently.
For more information visit www.fda.gov/ForConsumers/ByAudience/MinorityHealth/ucm472...
The 6 videos in this album (www.flickr.com/photos/fdaphotos/albums/72157669875514195) are downloadable from Flickr and free of all copyright restrictions. Redistribution of these videos via non-internet platforms is allowed. Credit to the U.S. Food and Drug Administration is appreciated but not required.
Drug development is a risky business. More than half of candidate drugs that look promising in the research lab will ultimately fail. More than a quarter of drugs that reach the clinical trial stage will be rejected as ineffective. However, the wealth of genomic information now available through public databases - in particular, the rapidly growing number of known associations between diseases and specific genes - may significantly improve the drug-development success rate. At least, success rates will improve if drug developers let genomics guide their choice of molecular targets for research, according to a team of pharmaceutical industry and academic scientists.
Credit: Ernesto del Aguila III, NHGRI.
For the “Year of Clinical Trial Diversity”, FDA is launching a series of educational videos and materials to raise awareness about the importance of minorities participating in clinical trials. These videos stress the importance of why diversity is needed to help ensure medical products are safe and effective for everyone. Ms. Miller, who is living with sickle cell disease explains why clinical trials need diverse people to discover health disparities—conditions that appear differently in minorities, or affect minorities more frequently.
For more information visit www.fda.gov/ForConsumers/ByAudience/MinorityHealth/ucm472...
This video is downloadable from Flickr and free of all copyright restrictions. Redistribution of this video via non-internet platforms is allowed. Credit to the U.S. Food and Drug Administration is appreciated but not required. To embed this video on your website, please use the YouTube embed code at www.youtube.com/watch?v=kIzOeZedkoA
For the “Year of Clinical Trial Diversity”, FDA is launching a series of educational videos and materials to raise awareness about the importance of minorities participating in clinical trials. These videos stress the importance of why diversity is needed to help ensure medical products are safe and effective for everyone. Ms. Miller, who is living with sickle cell disease explains why clinical trials need diverse people to discover health disparities—conditions that appear differently in minorities, or affect minorities more frequently.
For more information visit www.fda.gov/ForConsumers/ByAudience/MinorityHealth/ucm472...
This video is downloadable from Flickr and free of all copyright restrictions. Redistribution of this video via non-internet platforms is allowed. Credit to the U.S. Food and Drug Administration is appreciated but not required. To embed this video on your website, please use the YouTube embed code at www.youtube.com/watch?v=Q4iPlW0Glz0
For the “Year of Clinical Trial Diversity”, FDA is launching a series of educational videos and materials to raise awareness about the importance of minorities participating in clinical trials. These videos stress the importance of why diversity is needed to help ensure medical products are safe and effective for everyone. In this video, FDA’s Acting Chief Scientist, explains FDA’s role in increasing clinical trial diversity.
For more information visit www.fda.gov/ForConsumers/ByAudience/MinorityHealth/ucm472...
This video is downloadable from Flickr and free of all copyright restrictions. Redistribution of this video via non-internet platforms is allowed. Credit to the U.S. Food and Drug Administration is appreciated but not required. To embed this video on your website, please use the YouTube embed code at www.youtube.com/watch?v=wSjjS7M5jts
For the “Year of Clinical Trial Diversity”, FDA is launching a series of educational videos and materials to raise awareness about the importance of minorities participating in clinical trials. These videos stress the importance of why diversity is needed to help ensure medical products are safe and effective for everyone. Ms. Miller, who is living with sickle cell disease explains the benefits of participating in clinical trials.
For more information visit www.fda.gov/ForConsumers/ByAudience/MinorityHealth/ucm472...
This video is downloadable from Flickr and free of all copyright restrictions. Redistribution of this video via non-internet platforms is allowed. Credit to the U.S. Food and Drug Administration is appreciated but not required. To embed this video on your website, please use the YouTube embed code at www.youtube.com/watch?v=U1-3_5aYaMs
For the “Year of Clinical Trial Diversity”, FDA is launching a series of educational videos and materials to raise awareness about the importance of minorities participating in clinical trials. These videos stress the importance of why diversity is needed to help ensure medical products are safe and effective for everyone. Ms. Miller, who is living with sickle cell disease explains why healthy volunteers can participate in clinical trials.
For more information visit www.fda.gov/ForConsumers/ByAudience/MinorityHealth/ucm472...
This video is downloadable from Flickr and free of all copyright restrictions. Redistribution of this video via non-internet platforms is allowed. Credit to the U.S. Food and Drug Administration is appreciated but not required. To embed this video on your website, please use the YouTube embed code at www.youtube.com/watch?v=fkZ_4mwJLPM
For the “Year of Clinical Trial Diversity”, FDA is launching a series of educational videos and materials to raise awareness about the importance of minorities participating in clinical trials. These videos stress the importance of why diversity is needed to help ensure medical products are safe and effective for everyone. Ms. Miller, who is living with sickle cell disease explains how to find information on clinical trials.
For more information visit www.fda.gov/ForConsumers/ByAudience/MinorityHealth/ucm472...
This video is downloadable from Flickr and free of all copyright restrictions. Redistribution of this video via non-internet platforms is allowed. Credit to the U.S. Food and Drug Administration is appreciated but not required. To embed this video on your website, please use the YouTube embed code at www.youtube.com/watch?v=6FGGquOrVic
A computational model of a macromolecular complex. Scientists at the National Institute on Drug Abuse (NIDA), part of the NIH, have discovered macromolecular complexes that could enable medication development. The study changes long held concepts of cell decoding.
More information: www.nih.gov/news-events/news-releases/study-changes-long-...
Image credit: Dr. Sergi Ferre, NIDA, NIH
One of the first steps in drug development and toxicity testing is creating test systems (assays) to evaluate the effects of chemical compounds on cellular, molecular or biochemical processes of interest. Investigators from the biomedical research community submit ideas for assays to National Center for Advancing Translational Sciences researchers, who then assist with high-throughput small molecule screening using a robotic system.
ncats.nih.gov/preclinical/drugdev/assay
Credit: National Center for Advancing Translational Sciences, National Institutes of Health
Comparing the timeline for drug development and relationships. Relationship net expenditures were calculated at $50/week through year 6, then $100/week through to marriage, at an average wedding cost of $20,000. Average child costs are for 18 years. The figures are estimates, and the interest rate hasn't been accounted for. Various types of relationships couldn't be graphed together for sake of simplicity. Drug development data from PhRMA 2012 Industry Profile
Merging my hobby (photography) with my career (science)
Available for licensing through Getty Images:
www.gettyimages.com/detail/photo/image-of-dna-in-a-test-t...
Jonathan Goldsmith, M.D., F.A.C.P., was FDA’s Associate Director, Rare Diseases Program, Center for Drug Evaluation and Research.
This photo is free of all copyright restrictions and is available for use and redistribution without permission. Credit to the U.S. Food and Drug Administration is appreciated but not required. Privacy and use information: www.flickr.com/people/fdaphotos/
FDA photo by Michael J. Ermarth
Director, Office of Drug Development Partnership Programs
Office of the Director
View her staff profile: ncats.nih.gov/staff/ccolvis
Credit: National Center for Advancing Translational Sciences
George Harris Carter has had personal experience with the affects of sickle cell disease (SCD), leading him to be a patient advocate for over thirty years. SCD is an inherited blood disorder where normal round shaped red blood cells change to a sickled shape, ultimately blocking the flow of blood and oxygen to body parts and tissues leading to extreme pain. Lack of oxygen flow can also damage muscles, bones and internal organs and lead to other serious medical problems. George has dedicated himself to educating the public about SCD and providing patients with support by leading local the statewide Sickle Cell organization in his home state of Virginia. He has also been a strong advocate for drug development and clinical trials, serving as FDA Office of Special Health Issues (OSHI) Patient Representative for SCD.
For more information visit www.fda.gov/orphan.
The National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program was established in 2009 as a unique program that assists drug discovery by bridging the gap that often exists between basic research discoveries and the testing of new drugs in humans. The work of TRND includes the optimization and preclinical testing of therapies to generate sufficient quality data to support successful first-in-human studies. TRND stimulates research collaborations among NIH and academic scientists, nonprofit organizations, and pharmaceutical and biotechnology companies to foster the successful commercialization of new treatments for rare and neglected diseases.
For more information visit www.fda.gov/orphan.
FDA continues its long-standing commitment to rare diseases and developing diagnostics and therapeutics for those with unmet medical needs. The collective efforts of many individuals across the FDA have helped to bring over 400 rare disease products to the market ~approximately 1/3 of all new molecular entities a year. Through strong communication and collaboration across the rare disease community, FDA remains committed to strong regulatory science to maximize the contribution of and minimize the risk to patients who volunteer for clinical trials to advance products for rare disease patients.
For more information visit www.fda.gov/orphan.
Merging my hobby (photography) with my career (science).
Available for licensing through Getty Images:
www.gettyimages.com/detail/photo/scientists-hand-holding-...
Human dermal fibroblasts infected with virus expressing GFP viral tegument protein fusion (green) with cell counterstaining for actin (red) and DNA (blue).
The discovery, development, and clinical testing of products whether for rare or common diseases can be a long and expensive process. In the spirit of the Orphan Drug Act, since its passage, many contributors such as pharmaceutical companies, angel investors, foundations, venture capitalists, and academic/research organizations have come together to advance the development of over 400 products for rare diseases.
For more information visit www.fda.gov/orphan.
FDA’s Center for Drug Evaluation and Research (CDER) Rare Diseases Program was established in 2010 to facilitate and support research, development, regulation, and approval of CDER’s drug and biologic products for the treatment of rare disorders. The Program has served to coordinate the development of CDER policy, procedures, and training for the review and approval of treatments for rare diseases and works collaboratively with external and internal rare disease stakeholders to support the sound scientific development of treatments for rare disorders.
For more information visit www.fda.gov/orphan.
Representative Henry Waxman was the principal author of the original 1983 Orphan Drug Act (ODA). Senator Orrin Hatch was a co-sponsor and champion of the ODA. The ODA provided the first meaningful incentives to sponsors to develop needed medical products for the estimated 25 million Americans with rare diseases, defined under the ODA as diseases or conditions that affect fewer than 200,000 people in the United States. Fewer than 10 products supported by industry for rare diseases came to market between 1973 and 1983. Since its passage over 400 products for rare diseases have been approved.
For more information visit www.fda.gov/orphan.
Penguinone is an organic compound with the molecular formula C10H14O. Its name comes from the fact that its 2-dimensional molecular structure resembles a penguin. Penguinone has very little use commercially or in industry, however, it has been speculated that it could be used in drug development in the future.
Credit: www.ebi.ac.uk/chebi/
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
Participate in #medical and #scientific advancement in the making today! Contact Arysmed Today to qualify to participate in open #clinical studies in the NY | NJ area: info@arysmed.com (862) 247-8117 Ext 3001 www.arysmed.com
Linda Kinkel teaching students about broad spectrum vs narrow spectrum activity in antibiotcs
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
The Journal of Biomarkers in Drug Development (JBDD) promotes rigorous research that makes a significant contribution in advancing knowledge for Biomarkers in Drug Development. JBDD includes all major themes pertaining to Biomarkers used in Drug Development.
Debiopharm's Chief Scientific Officer, Dr. Andrés McAllister with Dr. David Deperthes the Director of Business Development & Licensing
Student measuring zone of inhibition of Streptomyces isolate against a pathogen.
Fill in your information:
[More information about the picture]
[Favorite story/memory about the picture]
Our representatives, Mr. Ajay Tandon, Dr. Venu Madhav Edupuganti and Mr. Rajkumar Agarwal would like to meet and discuss how we can facilitate your BA/BE Trial.
To schedule a meeting, please write to us at Rajkumar.Agarwal@veedacr.com.
Undergraduate students looking at their isolates
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
Carol Ishimaru teaching students broad spectrum vs narrow spectrum activity in antibiotcs
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]
A streptomyces isolate against a pathogen.
Fill in your information:
[More information about the picture]
[Favorite story/memory about the picture]
In-vitro Toxicity Testing in Drug Development
www.cognibrain.com/in-vitro-toxicity-testing-in-drug-deve...
A student measuring zones of inhibition
Fill in your information:
[Identify who is in this photo (left to right)]
[More information about those pictured]
[Favorite story/memory about those pictured/event pictured]